Our results comprehensively revealed the potential mechanism of SLC2A1 in pan-cancer, and they highlight the impact of SLC2A1 on the tumor microenvironment (TME) and cancer immunotherapy. The gene discussed is SLC2A1; the disease is neoplasm.